At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE
If cardiovascular studies are required for non-cardiac drugs, they should be focused on specific signals of heart-related concern that may not include ischemic events, advisory committee cardiologists say during review of Novo Nordisk’s Saxenda for obesity.
You may also be interested in...
EMPA-REG data for Boehringer/Lilly's Jardiance highlight need to rethink diabetes trials' current three-point MACE endpoint that is heavily focused on atherosclerosis, FDA advisors say.
Boehringer/Lilly's Jardiance delivers impressive CV death benefit but no effect on myocardial infarction or stroke – prompting questions about relevance of MACE composite primary endpoint.
Outcomes trials of AstraZeneca’s saxagliptin and Takeda’s alogliptin provide reassurance on cardiovascular risks but raise other safety concerns that are difficult to interpret due to the studies’ high-risk populations and ischemia-focused endpoints.